Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes

被引:189
|
作者
Yamazaki, H [1 ]
Inoue, K [1 ]
Hashimoto, M [1 ]
Shimada, T [1 ]
机构
[1] Osaka Prefectural Inst Publ Hlth, Higashinari Ku, Osaka 537, Japan
关键词
nicotine; CYP2A6; CYP2B6; human P450; liver microsomes;
D O I
10.1007/s002040050588
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Nicotine C-oxidation by recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes was investigated using a convenient high-performance liquid chromatographic method. Experiments with recombinant human P350 enzymes in baculovirus systems, which co-express human nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH)-P450 reductase, revealed that CYP2A6 had the highest nicotine C-oxidation activities followed by CYP2B6 and CYP2D6; the K-m values by these three P450 enzymes were determined to be 11.0, 105, and 132 mu M, respectively, and the V-max values to be 11.0, 8.2, and 8.6 nmol/min per nmol P450. respectively. CYP2E1, 2C19, 1A2, 2C8, 3A4, 2C9, and 1A1 catalysed nicotine C-oxidation only at high (500 mu M) substrate concentration. CYP1B1, 2C18, 3A5, and 4A11 had no measurable activities even at 500 mu M nicotine. In liver microsomes of 16 human samples, nicotine C-oxidation activities were correlated with CYP2A6 contents at 10 mu M substrate concentration, whereas such correlation coefficients were decreased when the substrate concentration was increased to 500 mu M. Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 CIM nicotine. CYP2D6 was found to have minor roles since quinidine did not inhibit microsomal nicotine C-oxidation at both 10 and 500 mu M substrate concentrations. These results support the view that CYP2A6 has major roles for nicotine C-oxidation at lower substrate concentration and both CYP2A6 and 2B6 play roles at higher substrate concentrations in human liver microsomes.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 50 条
  • [41] CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!
    Cook-Sather, Scott D.
    Adamson, Peter C.
    Li, Jin
    Hakonarson, Hakon
    ANESTHESIOLOGY, 2016, 125 (06) : 1085 - 1087
  • [42] Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
    Ford, Graeme R.
    Niehaus, Antoinette
    Joubert, Fourie
    Pepper, Michael S.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (12):
  • [43] The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients
    Tan, Lan
    Yu, Jin-Tai
    Sun, Yan-Ping
    Ou, Jiang-Rong
    Song, Jing-Hui
    Yu, Yang
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2010, 112 (04) : 320 - 323
  • [44] Characterisation of CYP2D6, CYP2B6 and CYP2A6 haplotype variation in African populations and development of the StellarPGx diplotype calling algorithm
    Twesigomwe, David
    Lombard, Zane
    Hazelhurst, Scott
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 692 - 693
  • [45] Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities
    Hosono, Hiroki
    Kumondai, Masaki
    Maekawa, Masamitsu
    Yamaguchi, Hiroaki
    Mano, Nariyasu
    Oda, Akifumi
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (03) : 279 - 285
  • [46] Association Between Nicotine Metabolism and CYP2A6*1 and CYP2A6*4 Genotypes in an Iranian Population
    Heravi, Reza Entezari
    Ramezani, Mohammad
    Behravan, Javad
    DNA AND CELL BIOLOGY, 2010, 29 (07) : 369 - 373
  • [47] Splicing errors contribute to phenotypic variability in CYP2B6 mediated metabolism in human liver microsomes
    Alrohaimi, A
    Court, MH
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1196 - 1196
  • [48] Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
    Mwenifiumbo, Jill C.
    Tyndale, Rachel F.
    PHARMACOGENOMICS, 2007, 8 (10) : 1385 - 1402
  • [49] Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity
    Oscarson, M
    McLellan, RA
    Asp, V
    Ledesma, M
    Ruiz, MLB
    Sinues, B
    Rautio, A
    Ingelman-Sundberg, M
    HUMAN MUTATION, 2002, 20 (04) : 275 - 283
  • [50] CYP2A6 polymorphism and nicotine metabolism.
    Benowitz, NL
    Tyndale, R
    Jacob, P
    Swan, GE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P41 - P41